Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development
Abeome Corp
Avacta Life Sciences Ltd
BJ Bioscience Inc
Boehringer Ingelheim Intertiol GmbH
Bristol-Myers Squibb Co
Crescendo Biologics Ltd
Eli Lilly and Co
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
GigaGen Inc
GlaxoSmithKline Plc
I-Mab Biopharma Co Ltd
ILGEN Inc
Immutep Ltd
Incyte Corp
Innovent Biologics Inc
Leads Biolabs Inc
Leidos Health
Lipid Genomics Inc
MacroGenics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Shanghai Henlius Biotech Inc
Stcube Inc
Sutro Biopharma Inc
Symphogen A/S
Xencor Inc
Y-Biologics
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles
(nivolumab + relatlimab) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abeome Corp, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by BJ Bioscience Inc, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Crescendo Biologics Ltd, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by F-star Biotechnology Ltd, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Fountain Biopharma Inc, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by ILGEN Inc, H2 2019
Pipeline by Immutep Ltd, H2 2019
Pipeline by Incyte Corp, H2 2019
Pipeline by Innovent Biologics Inc, H2 2019
Pipeline by Leads Biolabs Inc, H2 2019
Pipeline by Leidos Health, H2 2019
Pipeline by Lipid Genomics Inc, H2 2019
Pipeline by MacroGenics Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Stcube Inc, H2 2019
Pipeline by Sutro Biopharma Inc, H2 2019
Pipeline by Symphogen A/S, H2 2019
Pipeline by Xencor Inc, H2 2019
Pipeline by Y-Biologics, H2 2019
Dormant Projects, H2 2019